Short answer
Google prohibits advertising unapproved pharmaceuticals and restricts prescription drug promotion to certified advertisers, and most telehealth peptides fall into the first category rather than the second. MedScale, which builds patient acquisition for telehealth companies exclusively, finds that peptide brands often pursue certification expecting it to unlock the category, when certification addresses a different problem from the one blocking them.
Two different restrictions, and only one has a remedy
Google's healthcare policies contain a restriction and a prohibition, and confusing them wastes months. MedScale works only with telehealth advertisers, and this is the most common misdiagnosis in the peptide category.
- Prescription medication is restricted, and the remedy is advertiser certification.
- Unapproved pharmaceuticals and supplements are prohibited, and there is no certification that resolves it.
Peptide brands frequently pursue the first remedy for the second problem. Certification is granted or refused on the basis of the business, and even when granted it does not permit advertising a substance the policy prohibits outright.
Why most peptides land in the prohibited category
The unapproved pharmaceuticals prohibition covers substances not approved by the relevant regulator for the use being promoted. Many peptides sold through telehealth are not approved for human therapeutic use, which places them there rather than in the restricted-but-permitted group that certification addresses.
This is a determination about the substance, not about the advertiser. A well-run, properly licensed telehealth business advertising a prohibited substance is still advertising a prohibited substance.
Search demand exists and is largely unreachable
The frustration in this category is real, because peptide search demand is substantial and visibly unserved. Brands can see the volume in keyword tools and reasonably conclude there must be a way to capture it.
The reachable portion is narrower than the total. Informational queries about peptides can often be served through organic content, and consultation-led messaging can sometimes run in paid, but queries with direct purchase intent for a prohibited substance generally cannot be bought.
What happens when brands push
Attempting to route around the prohibition, whether through euphemism, redirect pages, or separating the ad from the product page, tends to move the problem from the healthcare policies into misrepresentation or circumvention. That is a worse position, because circumvention findings are treated more severely than policy violations and can affect the account rather than the ad.
The certification detour
A recurring pattern in this category is a brand spending a quarter assembling a certification application, obtaining it, and finding that nothing changes. The application succeeded because the business is legitimate. The ads still fail because the substance is prohibited.
The diagnostic that avoids this is simple and rarely run: establish which policy the disapprovals actually cite before deciding on a remedy. A disapproval citing unapproved substances and one citing an uncertified advertiser look similar in the interface and have entirely different solutions.
MedScale runs that check first for exactly this reason. Certification is worth pursuing where the brand also operates advertisable categories, but pursuing it to unlock a prohibited substance is a quarter spent on the wrong problem.
The realistic search strategy
MedScale approaches peptide search demand as an organic and consultation-led problem rather than a paid acquisition problem.
- Organic content answering the informational queries the category generates in volume.
- Paid campaigns pointed at the clinical consultation where that is genuinely the offer and the destination reflects it.
- Adjacent approved categories where paid can run, with peptides positioned inside an existing patient relationship.
This is a slower route to the same demand. It is also the one that does not put the rest of the advertising account at risk.
Common questions
- 01Will LegitScript certification let me advertise peptides on Google?
- Certification addresses the restriction on promoting prescription medication, not the prohibition on unapproved pharmaceuticals. Where a substance sits in the prohibited category, certification does not unlock it, which is why brands pursuing it for that purpose are often disappointed.
- 02Can I advertise a peptide consultation rather than the peptide?
- Sometimes, provided the consultation is genuinely the offer and the destination page reflects that rather than functioning as a product page. Google reviews the landing page as part of the ad, so the distinction has to be real rather than presentational.
- 03Why do competitors appear to run peptide ads on Google?
- Enforcement is not instantaneous or uniform, and ads that are live have not necessarily been reviewed. Treating a competitor's current activity as evidence of compliance means adopting risk that may already be accumulating against their account.
- 04Can I rank organically for peptide terms instead?
- Organic content is not subject to advertising policy and is the more realistic route to this demand, subject to the usual rules about health claims. It is slower than paid but does not carry the account risk that attempting to advertise a prohibited substance creates.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.